Table 3.
Pharmacokinetic profile of compound 14·3HCl in Sprague–Dawley rats.
| Route | t1/2 (h) | Tmax (h) | Cmax (ng/mL) | AUC(0−t) (h·ng/mL) | AUC(0−∞) (h·ng/mL) | MRT(0−t) (h) | CL (mL/h/kg) | F (%) |
|---|---|---|---|---|---|---|---|---|
| i.v.a | 6.7 ± 1.5 | 0.4 ± 0.4 | 230 ± 50 | 1666 ± 184 | 1819 ± 297 | 6.3 ± 0.8 | 1398 ± 217 | – |
| p.o.b | 5.2 ± 0.9 | 6.0 ± 2.0 | 272 ± 25 | 3310 ± 812 | 3551 ± 1008 | 8.4 ± 0.7 | – | 50 ± 12 |
AUC: area under the curve. MRT: mean residence time. CL: clearance. −Not applicable.
a
i.v. = intravenous administration, dose = 2.5 mg/kg.
b
p.o. = oral administration, dose = 10 mg/kg.